CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $30,851,538 | -28.5% | 679,699 | -11.5% | 0.00% | -25.0% |
Q2 2023 | $43,124,334 | +84.2% | 768,157 | +48.4% | 0.00% | +100.0% |
Q1 2023 | $23,415,843 | +35.1% | 517,706 | +21.4% | 0.00% | 0.0% |
Q4 2022 | $17,337,876 | -87.7% | 426,516 | -80.2% | 0.00% | -87.5% |
Q3 2022 | $140,436,000 | +35.1% | 2,148,982 | +25.6% | 0.02% | +45.5% |
Q2 2022 | $103,942,000 | +128.1% | 1,710,412 | +135.6% | 0.01% | +175.0% |
Q1 2022 | $45,575,000 | -18.1% | 726,049 | -1.2% | 0.00% | -20.0% |
Q4 2021 | $55,668,000 | -66.9% | 734,610 | -51.1% | 0.01% | -72.2% |
Q3 2021 | $168,048,000 | -3.4% | 1,501,373 | +39.8% | 0.02% | 0.0% |
Q2 2021 | $173,886,000 | +215.2% | 1,074,098 | +137.2% | 0.02% | +200.0% |
Q1 2021 | $55,170,000 | +2.5% | 452,767 | +28.8% | 0.01% | -14.3% |
Q4 2020 | $53,837,000 | +809.6% | 351,630 | +396.9% | 0.01% | +600.0% |
Q3 2020 | $5,919,000 | +2.8% | 70,771 | -9.6% | 0.00% | 0.0% |
Q2 2020 | $5,755,000 | +116.4% | 78,301 | +24.9% | 0.00% | – |
Q1 2020 | $2,659,000 | -7.7% | 62,682 | +32.5% | 0.00% | – |
Q4 2019 | $2,880,000 | -9.4% | 47,292 | -39.0% | 0.00% | – |
Q3 2019 | $3,180,000 | +304.6% | 77,576 | +365.0% | 0.00% | – |
Q2 2019 | $786,000 | -37.5% | 16,683 | -52.6% | 0.00% | – |
Q1 2019 | $1,257,000 | +666.5% | 35,165 | +514.9% | 0.00% | – |
Q4 2018 | $164,000 | -53.3% | 5,719 | -27.4% | 0.00% | – |
Q3 2018 | $351,000 | -36.5% | 7,879 | -16.2% | 0.00% | – |
Q2 2018 | $553,000 | +62.6% | 9,407 | +26.5% | 0.00% | – |
Q1 2018 | $340,000 | +44.7% | 7,435 | -25.9% | 0.00% | – |
Q4 2017 | $235,000 | +5.4% | 10,029 | -19.5% | 0.00% | – |
Q3 2017 | $223,000 | +12.1% | 12,462 | 0.0% | 0.00% | – |
Q2 2017 | $199,000 | -37.0% | 12,462 | -14.1% | 0.00% | – |
Q1 2017 | $316,000 | -27.5% | 14,512 | -32.5% | 0.00% | – |
Q4 2016 | $436,000 | – | 21,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |